A 52-year-old woman from Mumbai underwent exploratory laparotomy for a suspected ovarian mass. Intraoperative findings revealed a 6 cm left ovarian tumor with rupture of the capsule, ascites (200 mL), and involvement of the omentum. Frozen section confirmed high-grade serous adenocarcinoma. The surgeon performed total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and peritoneal biopsies. Postoperatively, she is staged as IIIC. Which of the following is the most appropriate next step in management?

Explanation

## Management of Stage IIIC Epithelial Ovarian Cancer ### Clinical Context This patient has undergone **optimal primary cytoreduction** (total abdominal hysterectomy, bilateral salpingo-oophorectomy, omentectomy, peritoneal biopsies) for Stage IIIC high-grade serous adenocarcinoma. The next critical decision is chemotherapy sequencing. ### Treatment Algorithm for Stage IIIC Ovarian Cancer ```mermaid flowchart TD A[Stage IIIC Epithelial Ovarian Cancer]:::outcome --> B{Optimal primary cytoreduction achieved?}:::decision B -->|Yes| C[Primary Adjuvant Chemotherapy]:::action B -->|No| D[Neoadjuvant Chemotherapy + Interval Cytoreduction]:::action C --> E[Platinum-Taxane Doublet]:::action E --> F[Paclitaxel 175 mg/m² + Carboplatin AUC 5-6]:::action F --> G[6 cycles, 3-weekly]:::action D --> H[3 cycles NACT, then reassess]:::action H --> I[Interval cytoreduction if feasible]:::action I --> J[3 more cycles adjuvant chemotherapy]:::action ``` ### Why Primary Adjuvant Chemotherapy? **Key Point:** This patient has achieved **optimal primary cytoreduction** — defined as residual disease ≤1 cm (ideally no visible residual disease). Optimal cytoreduction is the strongest prognostic factor in ovarian cancer. | Factor | Implication | |--------|-------------| | **Optimal primary cytoreduction achieved** | Proceed directly to primary adjuvant chemotherapy | | **Suboptimal cytoreduction (>1 cm residual)** | Consider neoadjuvant chemotherapy + interval cytoreduction | | **Unresectable disease** | Neoadjuvant chemotherapy mandatory | ### Standard Adjuvant Chemotherapy Regimen **High-Yield:** The gold-standard regimen for Stage III ovarian cancer is: 1. **Paclitaxel** 175 mg/m² IV over 3 hours 2. **Carboplatin** AUC 5–6 IV 3. **Schedule:** Every 3 weeks for 6 cycles 4. **Total duration:** ~18 weeks **Clinical Pearl:** Bevacizumab (anti-VEGF monoclonal antibody) is increasingly added to the platinum-taxane backbone in Stage III/IV disease (GOG-218, ICON7 trials), but the question stem does not mention this; the primary answer is platinum-taxane chemotherapy. ### Why NOT Neoadjuvant Chemotherapy? Neoadjuvant chemotherapy is reserved for: - **Unresectable disease** at presentation - **Suboptimal cytoreduction** (>1 cm residual) despite primary surgery - **Poor performance status** precluding aggressive surgery This patient has already achieved optimal cytoreduction, so neoadjuvant therapy is not indicated. ### Why NOT Observation Alone? **Warning:** Observation without adjuvant chemotherapy in Stage IIIC disease is associated with very poor outcomes (median overall survival ~2–3 years). Chemotherapy improves median OS to 4–5 years in Stage III disease. ### Why NOT Radiation Therapy? Radiation therapy has a limited role in ovarian cancer: - Not standard for Stage III disease - May be considered for isolated pelvic or abdominal recurrence - Whole-abdomen radiation is rarely used due to toxicity - Chemotherapy is superior for systemic disease control